AstraZeneca Wins FDA Approval for IMFINZI in Early Bladder Cancer
WILMINGTON, DE — AstraZeneca has secured U.S. regulatory approval for IMFINZI (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) therapy for adults with previously untreated high-risk non-muscle-invasive bladder cancer, expanding the …
AstraZeneca Wins FDA Approval for IMFINZI in Early Bladder Cancer Read More